Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 5/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976500 | 0.90 | P2RX7 (0.42) | KDM2BGBA1P2RX7LMNASMN1; SMN2 | |
| SCHEMBL4976331 | 0.89 | P2RX7 (0.47) | KDM2BP2RX7ALDH1A1HRH1HRH3 | |
| SCHEMBL4976392 | 0.89 | MEN1 (0.49) | P2RX7ALDH1A1HTTLMNAHRH1 | |
| SCHEMBL4977982 | 0.88 | KDM4E (0.53) | P2RX7ALDH1A1HTTCYP2C9CYP2C19 | |
| SCHEMBL4980177 | 0.86 | KCNK3 (0.49) | KDM2BP2RX7ALDH1A1HTTLMNA | |
| SCHEMBL4978484 | 0.85 | KDM2B (0.50) | KDM2BP2RX7ALDH1A1HRH1HRH3 | |
| SCHEMBL4974572 | 0.84 | P2RX7 (0.43) | P2RX7ALDH1A1HTTSMN1; SMN2HRH1 | |
| SCHEMBL4976388 | 0.83 | KDM2B (0.53) | KDM2BP2RX7ALDH1A1HTTHPGD | |
| SCHEMBL4978912 | 0.81 | KDM4E (0.55) | ALDH1A1HTTHPGDLMNASMN1; SMN2 | |
| SCHEMBL4978542 | 0.81 | KDM4E (0.47) | ALDH1A1LMNAHRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | KDM2B 1937/4885GBA1 3687/4885P2RX7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.